Shanghai Race announced that the company's SR604 injection clinical trial application for the addition of thrombocytopenia prevention and treatment was accepted by the State Drug Administration. The acceptance number is CXSL2601243. In the same period, the indications for “thrombocytopenia” and “prevention and treatment of vascular hemophilia” to be developed by SR604 injections will be included in the “Care Plan-Extension” pilot project. The announcement period ends on November 10, 2026. SR604 injection is a class 1 biological product for therapeutic use. Currently, 3 rare disease indications have been and/or are to be included in this pilot project. There is still uncertainty about related matters, so investors are requested to be aware of the risks.

Shanghai Race announced that the company's SR604 injection clinical trial application for the addition of thrombocytopenia prevention and treatment was accepted by the State Drug Administration. The acceptance number is CXSL2601243. In the same period, the indications for “thrombocytopenia” and “prevention and treatment of vascular hemophilia” to be developed by SR604 injections will be included in the “Care Plan-Extension” pilot project. The announcement period ends on November 10, 2026. SR604 injection is a class 1 biological product for therapeutic use. Currently, 3 rare disease indications have been and/or are to be included in this pilot project. There is still uncertainty about related matters, so investors are requested to be aware of the risks.